Lawrence J. Hineline - 18 Feb 2023 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role: SVP of Finance CFO
Signature: /s/ Lawrence J. Hineline
Issuer symbol: ITCI
Transactions as of: 18 Feb 2023
Net transactions value: -$2,491,342
Form type: 4
Filing time: 22 Feb 2023, 19:02:15 UTC
Previous filing: 23 Sep 2022
Next filing: 27 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITCI	Common Stock	Options Exercise	$687,013	+53,968		$12.73^*	53,968	17 Feb 2023	Direct
transaction	ITCI	Common Stock	Sale	$2,604,017	-52,279	-97%	$49.81	1,689	17 Feb 2023	Direct	F1, F2
transaction	ITCI	Common Stock	Sale	$85,447	-1,689	-100%	$50.59	0	17 Feb 2023	Direct	F1, F3
transaction	ITCI	Common Stock	Options Exercise		+10,443			10,443	18 Feb 2023	Direct	F4
transaction	ITCI	Common Stock	Sale	$402,524	-8,649	-83%	$46.54	1,794	21 Feb 2023	Direct	F5, F6
transaction	ITCI	Common Stock	Sale	$37,856	-800	-45%	$47.32	994	21 Feb 2023	Direct	F5, F7
transaction	ITCI	Common Stock	Sale	$43,848	-900	-91%	$48.72	94	21 Feb 2023	Direct	F5, F8
transaction	ITCI	Common Stock	Sale	$4,662	-94	-100%	$49.60	0	21 Feb 2023	Direct	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITCI	Stock Option (right to buy)	Options Exercise	$0	-53,968	-100%	$0.000000^*	0	17 Feb 2023	Common Stock	53,968	$12.73	Direct	F9
transaction	ITCI	Restricted Stock Units	Options Exercise	$0	-10,443	-100%	$0.000000^*	0	18 Feb 2023	Common Stock	10,443		Direct	F10, F11

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $50.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $50.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4	Restricted stock units convert into common stock on a one-for-one basis.
F5	This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
F6	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.14 to $47.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.16 to $48.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F8	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.28 to $48.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F9	All shares underlying this option have vested.
F10	Each restricted stock unit represents a contingent right to receive one share of common stock.
F11	On February 18, 2020, the reporting person was granted 31,328 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.